Treatment of cerebral ischemia-reperfusion injury with PEGylated liposomes encapsulating FK506

FASEB Journal

Volumn 27, Issue 4, 2013, Pages 1362-1370

  Ishii, Takayuki ^a   Asai, Tomohiro ^a   Oyama, Dai ^a   Agato, Yurika ^a   Yasuda, Nodoka ^a   Fukuta, Tatsuya ^a   Shimizu, Kosuke ^a   Minamino, Tetsuo ^b   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Apoptosis; Inflammation; Motor function; Neuroprotectant; Tacrolimus

Indexed keywords

HYDROGEN PEROXIDE; LIPOSOME; MACROGOL; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN INJURY; BRAIN ISCHEMIA; CELL PROTECTION; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRUG DELIVERY SYSTEM; ENCAPSULATION; HISTOPATHOLOGY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR PERFORMANCE; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; PARENCHYMA; PC12 CELL; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; HYDROGEN PEROXIDE; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIC ATTACK, TRANSIENT; LIPOSOMES; MALE; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; REPERFUSION INJURY; TACROLIMUS;

RATTUS;

EID: 84875760232     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-221325     Document Type: Article

References (34)

1. Wong, C. H., and Crack, P. J. (2008) Modulation of neuroinflammation and vascular response by oxidative stress following cerebral ischemia-reperfusion injury. Curr. Med. Chem. 15, 1-14.
2. Eltzschig, H. K., and Eckle, T. (2011) Ischemia and reperfusion- from mechanism to translation. Nat. Med. 17, 1391-1401.
3. Tuma, R. F., and Steffens, S. (2012) Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury. Curr. Pharm. Biotechnol. 13, 46-58.
4. Ginsberg, M. D. (2009) Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 40, S111-S114.
5. Ishii, T., Asai, T., Oyama, D., Fukuta, T., Yasuda, N., Shimizu, K., Minamino, T., and Oku, N. (2012) Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. J. Control. Release 160, 81-87.
6. Sharkey, J., and Butcher, S. P. (1994) Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 371, 336-339.
7. Furuichi, Y., Maeda, M., Moriguchi, A., Sawamoto, T., Kawamura, A., Matsuoka, N., Mutoh, S., and Yanagihara, T. (2003) Tacrolimus, a potential neuroprotective agent, ameliorates ischemic brain damage and neurologic deficits after focal cerebral ischemia in nonhuman primates. J. Cereb. Blood Flow Metab. 23, 1183-1194.
8. Szydlowska, K., Zawadzka, M., and Kaminska, B. (2006) Neuroprotectant FK506 inhibits glutamate-induced apoptosis of astrocytes in vitro and in vivo. J. Neurochem. 99, 965-975.
9. Morioka, M., Hamada, J., Ushio, Y., and Miyamoto, E. (1999) Potential role of calcineurin for brain ischemia and traumatic injury. Prog. Neurobiol. 58, 1-30.
10. Wang, H. G., Pathan, N., Ethell, I. M., Krajewski, S., Yamaguchi, Y., Shibasaki, F., McKeon, F., Bobo, T., Franke, T. F., and Reed, J. C. (1999) Ca2-induced apoptosis through calcineurin dephosphorylation of BAD. Science 284, 339-343.
11. Hashiguchi, A., Kawano, T., Yano, S., Morioka, M., Hamada, J., Sato, T., Shirasaki, Y., Ushio, Y., and Fukunaga, K. (2003) The neuroprotective effect of a novel calmodulin antagonist, 3-[2-[4-(3- chloro-2-methylphenyl)-1-piperazinyl] ethyl]-5, 6-dimethoxy-1-(4- imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate, in transient forebrain ischemia. Neuroscience 121, 379-386.
12. Kaminska, B., Gaweda-Walerych, K., and Zawadzka, M. (2004) Molecular mechanisms of neuroprotective action of immunosuppressants- facts and hypotheses. J. Cell. Mol. Med. 8, 45-58.
13. Chuang, Y. C., Tyagi, P., Huang, H. Y., Yoshimura, N., Wu, M., Kaufman, J., and Chancellor, M. B. (2011) Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. Neurourol. Urodyn. 30, 421-427.
14. Moffatt, S. D., McAlister, V., Calne, R. Y., and Metcalfe, S. M. (1999) Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. Transplantation 67, 1205-1208.
15. Longa, E. Z., Weinstein, P. R., Carlson, S., and Cummins, R. (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20, 84-91.
16. Zhang, N., Komine-Kobayashi, M., Tanaka, R., Liu, M., Mizuno, Y., and Urabe, T. (2005) Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 36, 2220- 2225.
17. Toung, T. J., Bhardwaj, A., Dawson, V. L., Dawson, T. M., Traystman, R. J., and Hurn, P. D. (1999) Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats. Stroke 30, 1279-1285.
18. Hunter, A. J., Hatcher, J., Virley, D., Nelson, P., Irving, E., Hadingham, S. J., and Parsons, A. A. (2000) Functional assessments in mice and rats after focal stroke. Neuropharmacology 39, 806-816.
19. Rosenberg, G. A., Estrada, E. Y., and Dencoff, J. E. (1998) Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29, 2189- 2195.
20. Dirnagl, U., Iadecola, C., and Moskowitz, M. A. (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22, 391-397.
21. Ishii, T., Asai, T., Urakami, T., and Oku, N. (2010) Accumulation of macromolecules in brain parenchyma in acute phase of cerebral infarction/reperfusion. Brain Res. 1321, 164-168.
22. Yura, H., Yoshimura, N., Hamashima, T., Akamatsu, K., Nishikawa, M., Takakura, Y., and Hashida, M. (1999) Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. J. Control. Release 57, 87-99.
23. Shiraga, T., Matsuda, H., Nagase, K., Iwasaki, K., Noda, K., Yamazaki, H., Shimada, T., and Funae, Y. (1994) Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem. Pharmacol. 47, 727-735.
24. Duzgune, scedil, and Nir, S. (1999) Mechanisms and kinetics of liposome-cell interactions. Adv. Drug Deliv. Rev. 40, 3-18.
25. Vertut-Doi, A., Ishiwata, H., and Miyajima, K. (1996) Binding and uptake of liposomes containing a poly(ethylene glycol) derivative of cholesterol (stealth liposomes) by the macrophage cell line J774: influence of PEG content and its molecular weight. Biochim. Biophys. Acta 1278, 19-28.
26. Noto, T., Furuichi, Y., Ishiye, M., Matsuoka, N., Aramori, I., Mutoh, S., and Yanagihara, T. (2007) Tacrolimus (FK506) limits accumulation of granulocytes and platelets and protects against brain damage after transient focal cerebral ischemia in rat. Biol. Pharm. Bull. 30, 313-317.
27. Li, J. Y., Furuichi, Y., Matsuoka, N., Mutoh, S., and Yanagihara, T. (2006) Tacrolimus (FK506) attenuates biphasic cytochrome c release and Bad phosphorylation following transient cerebral ischemia in mice. Neuroscience 142, 789-797.
28. Shichinohe, H., Kuroda, S., Abumiya, T., Ikeda, J., Kobayashi, T., Yoshimoto, T., and Iwasaki, Y. (2004) FK506 reduces infarct volume due to permanent focal cerebral ischemia by maintaining BAD turnover and inhibiting cytochrome c release. Brain Res. 1001, 51-59.
29. Dawson, T. M., Steiner, J. P., Dawson, V. L., Dinerman, J. L., Uhl, G. R., and Snyder, S. H. (1993) Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 90, 9808-9812.
30. Sahota, P., and Savitz, S. I. (2011) Investigational therapies for ischemic stroke: neuroprotection and neurorecovery. Neurotherapeutics 8, 434-451.
31. Asai, T., Matsushita, S., Kenjo, E., Tsuzuku, T., Yonenaga, N., Koide, H., Hatanaka, K., Dewa, T., Nango, M., Maeda, N., Kikuchi, H., and Oku, N. (2011) Dicetyl phosphate-tetraethylenepentamine- based liposomes for systemic siRNA delivery. Bioconjug. Chem. 22, 429-435.
32. Tan, M. L., Choong, P. F., and Dass, C. R. (2010) Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 31, 184-193.
33. Torres, E., Mainini, F., Napolitano, R., Fedeli, F., Cavalli, R., Aime, S., and Terreno, E. (2011) Improved paramagnetic liposomes for MRI visualization of pH triggered release. J. Control. Release 154, 196-202.
34. Micheli, M. R., Bova, R., Magini, A., Polidoro, M., and Emiliani, C. (2012) Lipid-based nanocarriers for CNS-targeted drug delivery. Recent Pat. CNS Drug Discov. 7, 71-86.